Niagen Bioscience Launches Program Targeting Accelerated Aging and Rare Genetic Diseases
NAGE•Niagen Bioscience has launched a pharmaceutical program focused on developing therapies for accelerated aging and rare genetic diseases. The initiative will advance novel therapeutic candidates through preclinical development leveraging the company’s proprietary platform.
1. Program Launch and Focus
Niagen Bioscience has initiated a pharmaceutical program targeting accelerated aging and a spectrum of rare genetic diseases. This effort marks the company’s first formal foray into therapeutic development beyond its existing research activities.
2. Platform and Development Path
The program will utilize Niagen’s proprietary technology platform to identify and optimize novel therapeutic candidates. Candidates will progress through preclinical evaluation with the aim of filing for Investigational New Drug applications following successful in vivo proof-of-concept studies.
